COMPANY

AiViva BioPharma

AiViva is a clinical stage biotech company founded in 2015 by four pharmaceutical industry veterans with more than 160 years of combined industry experience. From company website Source · Oct 12, 2026

Keywords: dermatology oncology ophthalmology Neovascular Age-related Macular Degeneration Scar Incision Neovascular (Wet) Age-Related Macular Degeneration Diabetic Macular Edema Macular Edema Keloid Excision Margin Superficial Basal Cell Carcinoma Nodular Basal Cell Carcinoma Nonmelanoma Skin Cancers Abdominal Wound (Morphologic Abnormality) Papulopustular Rosacea AIV007 AIV001

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

Jul 1, 2026 Trial start Phase 2: Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration source ↗
Mar 2, 2023 Trial start Phase 1: Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) source ↗
2021-07 Trial start Phase 1/Phase 2: A Safety and Efficacy Study to Evaluate Rosacea source ↗
Jun 23, 2021 Trial start Phase 1: Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy source ↗
Aug 28, 2020 Trial start Phase 1: Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration source ↗
Aug 18, 2020 Trial start Phase 1/Phase 2: Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype source ↗
Nov 5, 2018 Trial start Phase 1/Phase 2: A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision source ↗

Upcoming milestones

Jun 30, 2027 (ESTIMATED) · Phase 2 · Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration · NCT07557121

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT07557121	Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration	Phase 2	Not yet recruiting	Jul 1, 2026	Jun 30, 2027 (estimated)
NCT05698329	Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)	Phase 1	Active, not recruiting	Mar 2, 2023	Mar 3, 2025 (actual)
NCT04827875	Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy	Phase 1	Completed	Jun 23, 2021	Dec 15, 2022 (actual)
NCT04470726	Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype	Phase 1/Phase 2	Completed	Aug 18, 2020	Jun 20, 2023 (actual)
NCT04422899	Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration	Phase 1	Completed	Aug 28, 2020	Sep 29, 2021 (actual)
NCT03639883	A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision	Phase 1/Phase 2	Completed	Nov 5, 2018	Dec 4, 2019 (actual)
NCT03883945	A Safety and Efficacy Study to Evaluate Rosacea	Phase 1/Phase 2	Withdrawn	2021-07	2022-07 (estimated)